Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 25;11(13):3673.
doi: 10.3390/jcm11133673.

Lipoprotein(a): Insights for the Practicing Clinician

Pyotr Telyuk  1 , David Austin  1 , Ahai Luvai  2 , Azfar Zaman  3
Affiliations
Review

Lipoprotein(a): Insights for the Practicing Clinician

Pyotr Telyuk et al. J Clin Med. .

Abstract

Following the discovery of the Lipoprotein(a) (Lp(a)) molecule by Kare Berg in 1963, many physiological and pathological properties of this particle remain to be fully understood. Multiple population-based studies have demonstrated a correlation between elevated Lp(a) levels and the incidence of cardiovascular disease. Data extrapolated from the Copenhagen City Heart and ASTRONOMER studies also demonstrated the link between Lp(a) levels and the incidence and rate of progression of calcific aortic stenosis. Interest in Lp(a) has increased in recent years, partly due to new emerging therapies that can specifically reduce serum Lp(a) concentrations. Given the strong correlation between Lp(a) and CV disease from epidemiological studies, several international guidelines have also been updated to advocate Lp(a) testing in specific population groups. This review aims to highlight the importance of the role of Lp(a) in cardiovascular disease and discusses the potential of novel therapies in patients with elevated Lp(a) levels.

Keywords: cardiovascular disease; lipoprotein(a); thrombogenicity.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no conflict of interest exists.

Figures

Figure 1
Figure 1
Schematic representation of Lp(a) particle. Lp(a) is composed of apo(a) covalently linked to apo(b100).
See this image and copyright information in PMC

References

    1. Kostner K.M., Kostner G.M. Lipoprotein (a): A historical appraisal. J. Lipid Res. 2017;58:1–14. doi: 10.1194/jlr.R071571. - DOI - PMC - PubMed
    1. Emerging Risk Factors Collaboration. Erqou S., Kaptoge S., Perry P.L., Di Angelantonio E., Thompson A., White I.R., Marcovina S.M., Collins R., Thompson S.G., et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412–423. doi: 10.1001/jama.2009.1063. - DOI - PMC - PubMed
    1. Aguib Y., Suwaidi J.A. The Copenhagen City Heart Study (Østerbroundersøgelsen) Glob. Cardiol. Sci. Pract. 2015;2015:33. doi: 10.5339/gcsp.2015.33. - DOI - PMC - PubMed
    1. Capoulade R., Chan K.L., Yeang C., Mathieu P., Bossé Y., Dumesnil J.G., Tsimikas S. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis. J. Am. Coll. Cardiol. 2015;66:1236–1246. doi: 10.1016/j.jacc.2015.07.020. - DOI - PubMed
    1. Vavuranakis M.A., Jones S.R., Cardoso R., Gerstenblith G., Leucker T.M. The role of Lipoprotein(a) in cardiovascular disease: Current concepts and future perspectives. Hell. J. Cardiol. 2020;61:398–403. doi: 10.1016/j.hjc.2020.09.016. - DOI - PMC - PubMed

LinkOut - more resources